Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Heidenreich, Olaf  [Clear All Filters]
Journal Article
Fischer U, Förster M, Rinaldi A, Risch T, Sungalee S, Warnatz H-J, Bornhauser B, Gombert M, Kratsch C, Stütz AM, et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet. 2015.
Pal D, Blair H, Parker J, Hockney S, Beckett M, Singh M, Tirtakusuma R, Nelson R, McNeill H, Angel SH, et al. hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. Cell Rep Med. 2022;3(8):100717.
Swart LE, Fens MHAM, van Oort A, Waranecki P, L Casimiro DMata, Tuk D, Hendriksen M, van den Brink L, Schweighart E, Seinen C, et al. Increased Bone Marrow Uptake and Accumulation of Very-Late Antigen-4 Targeted Lipid Nanoparticles. Pharmaceutics. 2023;15(6).
Kellaway SG, Potluri S, Keane P, Blair HJ, Ames L, Worker A, Chin PS, Ptasinska A, Derevyanko PK, Adamo A, et al. Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth. Nat Commun. 2024;15(1):1359.
Schnoeder TM, Schwarzer A, Jayavelu AKumar, Hsu C-J, Kirkpatrick J, Döhner K, Perner F, Eifert T, Huber N, Arreba-Tutusaus P, et al. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. Blood. 2021.
Schoenherr C, Wohlan K, Dallmann I, Pich A, Hegermann J, Ganser A, Hilfiker-Kleiner D, Heidenreich O, Scherr M, Eder M. Stable depletion of RUNX1-ETO in Kasumi-1 cells induces expression and enhanced proteolytic activity of Cathepsin G and Neutrophil Elastase. PLoS One. 2019;14(12):e0225977.
Fidyt K, Pastorczak A, Goral A, Szczygiel K, Fendler W, Muchowicz A, Bartlomiejczyk MAdam, Madzio J, Cyran J, Graczyk-Jarzynka A, et al. Targeting the thioredoxin system as a novel strategy against B cell acute lymphoblastic leukemia. Mol Oncol. 2019.
Bell HL, Blair HJ, Singh M, Moorman AV, Heidenreich O, van Delft FW, Lunec J, Irving JAE. Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Cancer Cell Int. 2023;23(1):202.